---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-045111"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:45:08.644837+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FibroGen Phase 3 pamrevlumab trial for DMD fails to meet primary endpoint

## Summary
- Primary endpoint (NSAA total score change at week 52) not met: mean difference -0.528 points (p=0.5553).
- All secondary endpoints including stair climb velocity and 10-meter walk/run test also not met.
- Pamrevlumab was generally safe and well tolerated; SAEs 8.3% pamrevlumab vs 2.8% placebo.
- Company evaluating total data and will share full results at a future medical forum.
- Interim CEO Thane Wettig expressed disappointment and gratitude to trial participants.

## SEC filing metadata
- accession: 0000950170-23-045111
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023045111/0000950170-23-045111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023045111/fgen-20230829.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-045111
- JSON: https://secwatch.observer/filing/0000950170-23-045111.json
- Plain text: https://secwatch.observer/filing/0000950170-23-045111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.